守正创新 让中医好方变好药

Core Viewpoint - The innovative traditional Chinese medicine (TCM) product Yiqi Tongqiao Wan has successfully completed phase III clinical trials and is now available for treating allergic rhinitis, with plans for a large-scale real-world study involving 10,000 samples to validate its clinical efficacy [1][3]. Group 1: Product Development and Efficacy - Yiqi Tongqiao Wan is developed by integrating modern medicinal components from the effective formula "Allergy Decoction" and employs modern pharmaceutical techniques [2]. - Clinical trial results show significant efficacy, with a nasal discharge symptom disappearance rate of 52.65% and a tear symptom disappearance rate of 80.97%. Additionally, 30% of patients did not experience a recurrence of rhinitis within a year after two weeks of treatment [3]. Group 2: Quality Control and Technological Integration - The quality of raw materials is crucial for modern pharmaceutical companies, and Yiqi Tongqiao Wan's 14 ingredients are sourced from high-quality regions and standardized cultivation bases [5]. - The production process utilizes digital technology for quality traceability throughout the entire supply chain, enhancing the stability and uniformity of the extract's quality [5][6]. Group 3: Market Expansion and Cultural Promotion - The company is expanding the application of TCM by developing diverse product lines, including health foods and beverages that incorporate TCM ingredients [8]. - Efforts to promote TCM culture include public health services and community engagement activities, aiming to enhance public understanding and acceptance of TCM [8].